PURPOSE: To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission. DESIGN: Retrospective cohort study. METHODS: Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at ≥2 visits spanning ≥90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis. RESULTS: Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4-10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42-4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years ago] =3.82; 95% CI, 1.91-7.63), age ≥45 years (HR [vs age <45 years] = 1.79; 95% CI, 1.03-3.11), female sex (HR = 1.61; 95% CI, 1.04-2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23-6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status were not associated with differential incidence. CONCLUSIONS: Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission.
Immunology and Uveitis
Remission of Intermediate Uveitis: Incidence and Predictive Factors. Am J Ophthalmol 2016;164:110-117.e2.Abstract
.
Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol 2016;100(1):135-41.Abstract
.
Current Treatment Modalities of JIA-associated Uveitis and its Complications: Literature Review. Ocul Immunol Inflamm 2016;24(4):431-9.Abstract
.
Rituximab in the Treatment of Refractory Noninfectious Scleritis. Am J Ophthalmol 2016;164:22-8.Abstract
.
Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature. Clin Rheumatol 2016;35(1):251-8.Abstract
.
Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016;15(4):457-65.Abstract
.
Short-Wavelength Automated Perimetry Parameters at Baseline and Following Remission in Patients With Birdshot Retinochoroidopathy. Am J Ophthalmol 2016;163:83-92.e6.Abstract
.
The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol 2016;61(1):1-17.Abstract
.
A therapeutic trial of valganciclovir in patients with uveitis and positive Epstein-Barr virus early antigen D IgG titers. Eur J Ophthalmol 2015;26(1):30-5.Abstract
.
Posterior Necrotizing Scleritis Presenting as Sectoral Chorioretinitis. Ocul Immunol Inflamm 2015;23(5):412-5.
.
The Risk of Intraocular Pressure Elevation inPediatric Noninfectious Uveitis. Ophthalmology 2015;122(10):1987-2001.Abstract
.
Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol 2015;60(6):575-89.Abstract
.